California, US & Barcelona, Spain — October 13th, 2025 — Together with eMolecules we announce the launch of a new integrated solution combining ExaScreen® with
Cambridge, UK & Barcelona, Spain — August 27th, 2025 — Domainex, a leading integrated drug discovery services company, and Pharmacelera, a pioneer
We are thrilled to announce a collaboration between Pharmacelera and the UMass Chan Medical School aimed to support early-stage drug discovery projects.
3D quantum-mechanics, molecular descriptors, and artificial intelligence provide unique capabilities in the chemical space to identify and qualify novel hits PALO ALTO,
DyNAbind and Pharmacelera are happy to announce a joint scientific collaboration in the fields of DNA-Encoded Libraries (DEL) and Artificial Intelligence (AI)
By Giorgia Zaetta – March. 9, 2021 The challenges of CNS Drug Discovery In the last decades, few clinically active drugs for brain disorders were identified, and many research projects have been abandoned because of drawbacks in the drug
Tautomerism, ionization and chirality are important factors to consider when building a compound library or when finding new hits. Tautomerism and ionization The
Pim-1 is an oncogene-encoded serine/threonine kinase. Originally identified in Maloney murine leukaemia, it is involved in several cellular functions associated with survival
